Equillium (EQ) News Today $0.72 +0.02 (+2.86%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Leerink Partnrs Predicts Increased Earnings for EquilliumNovember 18 at 2:31 AM | americanbankingnews.comEquillium reports Q3 EPS 0c, consensus (26c)November 14, 2024 | markets.businessinsider.comEquillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical UpdatesNovember 13, 2024 | businesswire.comEquillium Announces Poster Presentation at the Society for Immunotherapy of CancerNovember 12, 2024 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Equillium (EQ), Quest Diagnostics (DGX) and Alnylam Pharma (ALNY)November 5, 2024 | markets.businessinsider.comEquillium (EQ) Gets a Buy from Stifel NicolausNovember 5, 2024 | markets.businessinsider.comJones Trading Downgrades Equillium (EQ)November 1, 2024 | msn.comEquillium temporarily pausing EQUATOR enrollment to review clinical optionsNovember 1, 2024 | markets.businessinsider.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 0.90%October 31, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.90%October 31, 2024 | msn.comEquillium says Ono not acquiring itolizumab, stock craters 36%October 31, 2024 | msn.comInvestors Await Key Inflation, Employment Data as US Futures Move Lower in Thursday's PremarketOctober 31, 2024 | msn.comEquillium Maintains Rights to Itolizumab Following Ono PartnershipOctober 31, 2024 | finance.yahoo.comEquillium, Inc. (NASDAQ:EQ) COO Sells $18,750.00 in StockOctober 31, 2024 | insidertrades.comEquillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of CancerOctober 7, 2024 | finance.yahoo.comEquillium (NASDAQ:EQ) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comPenny Tom Sells 38,806 Shares of Equillium, Inc. (NASDAQ:EQ) StockSeptember 18, 2024 | insidertrades.comEquillium collaborates with Vivtex for oral formulation of autoimmune therapySeptember 17, 2024 | msn.comEquillium to Present at the Stifel Virtual Inflammation & Immunology SummitSeptember 10, 2024 | finance.yahoo.comEquillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor ConferenceAugust 28, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)August 19, 2024 | markets.businessinsider.comEquillium Second Quarter 2024 Earnings: Beats ExpectationsAugust 11, 2024 | finance.yahoo.comEquillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical HighlightsAugust 9, 2024 | finance.yahoo.comEQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q2 2024August 9, 2024 | markets.businessinsider.comEquillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host DiseaseAugust 6, 2024 | finance.yahoo.comAlopecia Areata Tied to Higher Risks of Autoimmune and Psychiatric ComorbiditiesJuly 31, 2024 | msn.comEquillium Announces Second Quarter 2024 Estimated Cash and Investments BalanceJuly 20, 2024 | finance.yahoo.comEquillium to be included in the Russell Microcap® IndexJune 12, 2024 | businesswire.comEquillium's (EQ) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Equillium in a report on Wednesday.June 5, 2024 | marketbeat.comEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 5, 2024 | businesswire.com3 Biotech Stocks Under $20 Worth Watching in JuneMay 31, 2024 | stocknews.comDecheng Capital LLC Purchases New Stake in Equillium, Inc. (NASDAQ:EQ)Decheng Capital LLC purchased a new stake in Equillium, Inc. (NASDAQ:EQ - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,447,308 shares of the company's stock, valued at approximately $3,May 30, 2024 | marketbeat.comEquillium to Present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | businesswire.comGraft versus Host Disease (GvHD) Pipeline Insights Report, 2024: Reveals 60+ Companies Engaged in Advancing 65+ Pipeline DrugsMay 28, 2024 | finance.yahoo.comBuy Rating Affirmed for Equillium on Milestones and Financial ProspectsMay 17, 2024 | markets.businessinsider.comEquillium (NASDAQ:EQ) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Equillium in a report on Friday.May 17, 2024 | marketbeat.comBuy Rating on Equillium as Promising Trials and Financial Stability Signal Upside PotentialMay 14, 2024 | markets.businessinsider.comEquillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host DiseaseMay 14, 2024 | businesswire.comEQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | msn.comEquillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical HighlightsMay 9, 2024 | businesswire.comBuy Rating Affirmed for Equillium on Strong itolizumab Data and Promising EQ101 Phase 2 ProspectsMay 9, 2024 | markets.businessinsider.comWe're Keeping An Eye On Equillium's (NASDAQ:EQ) Cash Burn RateMay 2, 2024 | finance.yahoo.comQ2 2024 EPS Estimates for Equillium, Inc. Lowered by HC Wainwright (NASDAQ:EQ)Equillium, Inc. (NASDAQ:EQ - Free Report) - Research analysts at HC Wainwright cut their Q2 2024 earnings per share (EPS) estimates for shares of Equillium in a research report issued on Tuesday, April 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($April 4, 2024 | marketbeat.comEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 3, 2024 | businesswire.comBuy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial UpsidesApril 3, 2024 | markets.businessinsider.comBiotech Rallies Strongly On Second Consecutive Positive HeadlineApril 2, 2024 | msn.comEquillium (NASDAQ:EQ) Price Target Raised to $5.00 at HC WainwrightHC Wainwright lifted their target price on Equillium from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday.April 2, 2024 | marketbeat.comEquillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus NephritisApril 1, 2024 | finance.yahoo.comEquities Analysts Offer Predictions for Equillium, Inc.'s Q3 2024 Earnings (NASDAQ:EQ)Equillium, Inc. (NASDAQ:EQ - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2024 earnings per share estimates for Equillium in a research note issued on Monday, March 25th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of $0.58 per shaMarch 28, 2024 | marketbeat.comEquillium Shares Fall After Swing to 4Q LossMarch 27, 2024 | marketwatch.com Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! EQ Media Mentions By Week EQ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EQ News Sentiment▼0.380.45▲Average Medical News Sentiment EQ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EQ Articles This Week▼61▲EQ Articles Average Week Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kezar Life Sciences News Today Coya Therapeutics News Today Monopar Therapeutics News Today Nuvectis Pharma News Today Eupraxia Pharmaceuticals News Today Anixa Biosciences News Today Karyopharm Therapeutics News Today Eliem Therapeutics News Today Coherus BioSciences News Today Immunic News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EQ) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
